Human islet isolation and allotransplantation in 22 consecutive cases

Camillo Ricordi, A. G. Tzakis, P. B. Carroll, Y. Zeng, H. L R Rilo, Rodolfo Alejandro, R. Shapiro, J. J. Fung, A. J. Demetris, D. H. Mintz, T. E. Starzl

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

This report provides our initial experience in islet isolation and intrahepatic allotransplantation in 21 patients. In group 1, 10 patients underwent combined liver-islet allotransplantation following upper-abdominal exenteration for cancer. In group 2, 4 patients received a combined liver- islet allograft for cirrhosis and diabetes. One patient had plasma C-peptide >3 pM and was therefore excluded from analysis. In group 3, 7 patients received 8 combined cadaveric kidney-islet grafts (one retransplant) for end- stage renal disease secondary to type 1 diabetes mellitus. The islets were separated by a modification of the automated method for human islet isolation and the preparations were infused into the portal vein. Immunosuppression was with FK506 (group 1) plus steroids (groups 2 and 3). Six patients in group 1 did not require insulin treatment for 5 to >16 months. In groups 2 and 3 none of the patients became insulin-independent, although decreased insulin requirement and stabilization of diabetes were observed. Our results indicate that rejection is still a major factor limiting the clinical application of islet transplantation in patients with type 1 diabetes mellitus, although other factors such as steroid treatment may contribute to deteriorate islet engraftment and/or function.

Original languageEnglish
Pages (from-to)407-414
Number of pages8
JournalTransplantation
Volume53
Issue number2
StatePublished - Jan 1 1992

Fingerprint

Insulin
Type 1 Diabetes Mellitus
Steroids
Islets of Langerhans Transplantation
C-Peptide
Liver
Tacrolimus
Portal Vein
Immunosuppression
Chronic Kidney Failure
Allografts
Fibrosis
Transplants
Kidney
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Transplantation

Cite this

Ricordi, C., Tzakis, A. G., Carroll, P. B., Zeng, Y., Rilo, H. L. R., Alejandro, R., ... Starzl, T. E. (1992). Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation, 53(2), 407-414.

Human islet isolation and allotransplantation in 22 consecutive cases. / Ricordi, Camillo; Tzakis, A. G.; Carroll, P. B.; Zeng, Y.; Rilo, H. L R; Alejandro, Rodolfo; Shapiro, R.; Fung, J. J.; Demetris, A. J.; Mintz, D. H.; Starzl, T. E.

In: Transplantation, Vol. 53, No. 2, 01.01.1992, p. 407-414.

Research output: Contribution to journalArticle

Ricordi, C, Tzakis, AG, Carroll, PB, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Demetris, AJ, Mintz, DH & Starzl, TE 1992, 'Human islet isolation and allotransplantation in 22 consecutive cases', Transplantation, vol. 53, no. 2, pp. 407-414.
Ricordi C, Tzakis AG, Carroll PB, Zeng Y, Rilo HLR, Alejandro R et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation. 1992 Jan 1;53(2):407-414.
Ricordi, Camillo ; Tzakis, A. G. ; Carroll, P. B. ; Zeng, Y. ; Rilo, H. L R ; Alejandro, Rodolfo ; Shapiro, R. ; Fung, J. J. ; Demetris, A. J. ; Mintz, D. H. ; Starzl, T. E. / Human islet isolation and allotransplantation in 22 consecutive cases. In: Transplantation. 1992 ; Vol. 53, No. 2. pp. 407-414.
@article{a93ea61beb8a457c893dbea792caefee,
title = "Human islet isolation and allotransplantation in 22 consecutive cases",
abstract = "This report provides our initial experience in islet isolation and intrahepatic allotransplantation in 21 patients. In group 1, 10 patients underwent combined liver-islet allotransplantation following upper-abdominal exenteration for cancer. In group 2, 4 patients received a combined liver- islet allograft for cirrhosis and diabetes. One patient had plasma C-peptide >3 pM and was therefore excluded from analysis. In group 3, 7 patients received 8 combined cadaveric kidney-islet grafts (one retransplant) for end- stage renal disease secondary to type 1 diabetes mellitus. The islets were separated by a modification of the automated method for human islet isolation and the preparations were infused into the portal vein. Immunosuppression was with FK506 (group 1) plus steroids (groups 2 and 3). Six patients in group 1 did not require insulin treatment for 5 to >16 months. In groups 2 and 3 none of the patients became insulin-independent, although decreased insulin requirement and stabilization of diabetes were observed. Our results indicate that rejection is still a major factor limiting the clinical application of islet transplantation in patients with type 1 diabetes mellitus, although other factors such as steroid treatment may contribute to deteriorate islet engraftment and/or function.",
author = "Camillo Ricordi and Tzakis, {A. G.} and Carroll, {P. B.} and Y. Zeng and Rilo, {H. L R} and Rodolfo Alejandro and R. Shapiro and Fung, {J. J.} and Demetris, {A. J.} and Mintz, {D. H.} and Starzl, {T. E.}",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "53",
pages = "407--414",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Human islet isolation and allotransplantation in 22 consecutive cases

AU - Ricordi, Camillo

AU - Tzakis, A. G.

AU - Carroll, P. B.

AU - Zeng, Y.

AU - Rilo, H. L R

AU - Alejandro, Rodolfo

AU - Shapiro, R.

AU - Fung, J. J.

AU - Demetris, A. J.

AU - Mintz, D. H.

AU - Starzl, T. E.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - This report provides our initial experience in islet isolation and intrahepatic allotransplantation in 21 patients. In group 1, 10 patients underwent combined liver-islet allotransplantation following upper-abdominal exenteration for cancer. In group 2, 4 patients received a combined liver- islet allograft for cirrhosis and diabetes. One patient had plasma C-peptide >3 pM and was therefore excluded from analysis. In group 3, 7 patients received 8 combined cadaveric kidney-islet grafts (one retransplant) for end- stage renal disease secondary to type 1 diabetes mellitus. The islets were separated by a modification of the automated method for human islet isolation and the preparations were infused into the portal vein. Immunosuppression was with FK506 (group 1) plus steroids (groups 2 and 3). Six patients in group 1 did not require insulin treatment for 5 to >16 months. In groups 2 and 3 none of the patients became insulin-independent, although decreased insulin requirement and stabilization of diabetes were observed. Our results indicate that rejection is still a major factor limiting the clinical application of islet transplantation in patients with type 1 diabetes mellitus, although other factors such as steroid treatment may contribute to deteriorate islet engraftment and/or function.

AB - This report provides our initial experience in islet isolation and intrahepatic allotransplantation in 21 patients. In group 1, 10 patients underwent combined liver-islet allotransplantation following upper-abdominal exenteration for cancer. In group 2, 4 patients received a combined liver- islet allograft for cirrhosis and diabetes. One patient had plasma C-peptide >3 pM and was therefore excluded from analysis. In group 3, 7 patients received 8 combined cadaveric kidney-islet grafts (one retransplant) for end- stage renal disease secondary to type 1 diabetes mellitus. The islets were separated by a modification of the automated method for human islet isolation and the preparations were infused into the portal vein. Immunosuppression was with FK506 (group 1) plus steroids (groups 2 and 3). Six patients in group 1 did not require insulin treatment for 5 to >16 months. In groups 2 and 3 none of the patients became insulin-independent, although decreased insulin requirement and stabilization of diabetes were observed. Our results indicate that rejection is still a major factor limiting the clinical application of islet transplantation in patients with type 1 diabetes mellitus, although other factors such as steroid treatment may contribute to deteriorate islet engraftment and/or function.

UR - http://www.scopus.com/inward/record.url?scp=0026578207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026578207&partnerID=8YFLogxK

M3 - Article

C2 - 1738936

AN - SCOPUS:0026578207

VL - 53

SP - 407

EP - 414

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -